Veracyte, Inc. (VCYT)
Market: NASD |
Currency: USD
Address: 6000 Shoreline Court
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Show more
📈 Veracyte, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$41.90
-
Upside/Downside from Analyst Target:
56.23%
-
Broker Call:
18
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
100-200%
-
Net Income Growth Range (1Y):
100-200%
-
Revenue Growth Range (1Y):
10-25%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Veracyte, Inc.
Date | Reported EPS |
---|
2026-02-23 (estimated upcoming) | - |
2025-11-04 (estimated upcoming) | - |
2025-08-04 (estimated upcoming) | - |
2025-05-07 | 0.09 |
2025-02-24 | 0.06 |
2024-11-06 | 0.19 |
2024-08-06 | 0.07 |
2024-05-07 | -0.02 |
2024-02-22 | -0.39 |
2023-11-07 | -0.41 |
2023-08-08 | -0.12 |
2023-05-04 | -0.11 |
2023-02-22 | -0.05 |
2022-11-02 | -0.12 |
2022-08-02 | -0.13 |
2022-05-03 | -0.2 |
2022-02-28 | -0.15 |
2021-11-09 | -0.2 |
2021-07-29 | -0.13 |
2021-05-10 | -0.11 |
2021-02-17 | -0.14 |
2020-11-02 | -0.08 |
2020-07-30 | -0.22 |
2020-05-06 | -0.24 |
2020-02-25 | -0.15 |
📰 Related News & Research
No related articles found for "veracyte inc".